Drug development for anxiety disorders: new roles for atypical antipsychotics.

Drug development for anxiety disorders: new roles for atypical antipsychotics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug development for anxiety disorders: new roles for atypical antipsychotics. Abstract Text:

William H Carson,Hisashi Kitagawa,Charles B Nemeroff,

Anxiety disorders are prevalent and frequently comorbid with depression. Rates of response and remission for anxiety disorders are low despite marked improvements in treatment in the past several decades. Antidepressants and anxiolytics remain the most frequently prescribed agents for anxiety disorders, but the numbers of prescriptions for novel forms of therapy, such as anticonvulsants and atypical antipsychotics are increasing. For the atypical antipsychotics, agonist activity at the 5-HT(1A) receptor has been hypothesized to translate into anxiolytic effects. A small, but growing, literature suggests that atypical antipsychotics are useful as augmentation therapy for treatment of refractory anxiety disorders. The next generation antipsychotic, aripiprazole, has a unique mechanism of action (ie, combined D(2) and 5-HT(1A) partial agonist and 5-HT(2A) antagonist) and improves depressive and depressive/anxiety symptoms in patients with schizophrenia. Further studies examining the effect of aripiprazole and other atypical antipsychotic drugs on depressive and anxiety symptoms in patients with refractory anxiety disorders are warranted.

Drug development for anxiety disorders: new roles for atypical antipsychotics. Publishing Authors By Initials

WH Carson,H Kitagawa,CB Nemeroff,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Drug development for anxiety disorders: new roles for atypical antipsychotics. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Psychopharmacology bulletin

VOLUME: 38 Suppl 1

Page Numbers: 38-45

Journal Abbreviation:

ISSN: 0048-5764

DAY: 26

MONTH: 10

YEAR: 2004

Drug development for anxiety disorders: new roles for atypical antipsychotics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101123

Drug development for anxiety disorders: new roles for atypical antipsychotics. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Drug development for anxiety disorders: new roles for atypical antipsychotics. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Drug development for anxiety disorders: new roles for atypical antipsychotics.

AFFILIATION: Global Product Development/Aripiprazole, Princeton Aripiprazole Unit, Otsuka America Pharmaceutical, Inc., in Princeton, NJ.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Psychopharmacol Bull

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug development for anxiety disorders: new roles for atypical antipsychotics Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.